SLPI and neoplasm: The elastase and serine protease inhibitor Secretory Leukocyte Protease Inhibitor (SLPI) was considerably reduced in OSCC compared with normal oral epithelium, and cancer cells treated in vitro with SLPI had reduced invasive ability, suggesting that SLPI is a therapeutic lead as it may decrease many tumor-promoting events (145).